Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,823 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,205 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | approved for marketing | — | — | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT04220203 | Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer | approved for marketing | — | — | Seagen, a wholly owned subsidiary of PfizerINDUSTRY |
| 0 |
| Jun 26, 2025 |
| clinicaltrials |
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 | May 20, 2025 | clinicaltrials |
| NCT03133988 | Margetuximab Expanded Access Program | approved for marketing | — | — | TerSera Therapeutics LLCINDUSTRY | 0 | Feb 14, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 | clinicaltrials |
| NCT02065765 | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 5 | Jan 9, 2025 | clinicaltrials |
| NCT02307812 | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Jan 9, 2025 | clinicaltrials |
| NCT00906984 | TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma(TheraSphere) | approved for marketing | — | — | University of California, IrvineOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05345678 | Himalaya Early Access Program | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04395508 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT04320693 | Expanded Access for IMMU-132 | approved for marketing | — | — | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT04377152 | Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT02436044 | HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC | approved for marketing | — | — | Ming ZhaoOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT00130897 | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | approved for marketing | — | — | PfizerINDUSTRY | 50 | Mar 9, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials